Estudio observacional sobre la influencia de los inhibidores de la bomba de protones en la incidencia de episodios cardiovasculares en pacientes tratados con clopidogrel

A. Gil Valiño , A.B. Ponce Piñón , M. Rodríguez Barreiro
{"title":"Estudio observacional sobre la influencia de los inhibidores de la bomba de protones en la incidencia de episodios cardiovasculares en pacientes tratados con clopidogrel","authors":"A. Gil Valiño ,&nbsp;A.B. Ponce Piñón ,&nbsp;M. Rodríguez Barreiro","doi":"10.1016/S2172-3761(11)70038-3","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>To analyze the ratio of hospitalizations (NH) due to cardiovascular events (CE) and mortality in patients treated with clopidogrel in association or not to a proton pump inhibitors (PPI).</p></div><div><h3>Material and methods</h3><p>A retrospective cohort study was performed. Patients who were taking clopidogrel and who belonged to four health centers in PC in two different health areas from Galicia (the data was obtained of the health care homologation program of prescriptions from the Sub-Department of Pharmacy) were selected. The study period included January 2007-March 2009. Computerized medical records and records in paper format were analyzed to determine the prescription of PPI and whether the patient had any NH as a result of CE (AMI, ACS, stroke, TIA, bypass, stroke and/or peripheral artery disease). The data were analyzed using the SPSS statistical program and a descriptive and statistical analysis was performed (CHI-square test and ANOVA test).</p></div><div><h3>Results</h3><p>A total of 304 patients who fulfilled the inclusion criteria (65.5% male and 34.5% women) were enrolled. A total of 58.6% of the patients were treated with clopidogrel and a PPI. Of these 58.6% required hospitalization due to a CE versus 14.3%, when no PPI was associated. This means a 2.1 times higher risk of suffering a NH. Omeprazole was the PPI most used (73.65%).</p></div><div><h3>Conclusions</h3><p>The results obtained indicate a probable interaction between PPI and clopidogrel, it not being possible to establish its clinical importance. This does not imply that it may have serious repercussions for the health of the patients.</p></div>","PeriodicalId":100520,"journal":{"name":"Farmacéuticos de Atención Primaria","volume":"9 3","pages":"Pages 76-80"},"PeriodicalIF":0.0000,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S2172-3761(11)70038-3","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Farmacéuticos de Atención Primaria","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2172376111700383","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Objective

To analyze the ratio of hospitalizations (NH) due to cardiovascular events (CE) and mortality in patients treated with clopidogrel in association or not to a proton pump inhibitors (PPI).

Material and methods

A retrospective cohort study was performed. Patients who were taking clopidogrel and who belonged to four health centers in PC in two different health areas from Galicia (the data was obtained of the health care homologation program of prescriptions from the Sub-Department of Pharmacy) were selected. The study period included January 2007-March 2009. Computerized medical records and records in paper format were analyzed to determine the prescription of PPI and whether the patient had any NH as a result of CE (AMI, ACS, stroke, TIA, bypass, stroke and/or peripheral artery disease). The data were analyzed using the SPSS statistical program and a descriptive and statistical analysis was performed (CHI-square test and ANOVA test).

Results

A total of 304 patients who fulfilled the inclusion criteria (65.5% male and 34.5% women) were enrolled. A total of 58.6% of the patients were treated with clopidogrel and a PPI. Of these 58.6% required hospitalization due to a CE versus 14.3%, when no PPI was associated. This means a 2.1 times higher risk of suffering a NH. Omeprazole was the PPI most used (73.65%).

Conclusions

The results obtained indicate a probable interaction between PPI and clopidogrel, it not being possible to establish its clinical importance. This does not imply that it may have serious repercussions for the health of the patients.

质子泵抑制剂对氯吡格雷治疗患者心血管发作发生率影响的观察研究
目的分析氯吡格雷联合或不联合质子泵抑制剂(PPI)治疗的患者因心血管事件(CE)住院的比率和死亡率。材料和方法进行回顾性队列研究。选择了正在服用氯吡格雷的患者,这些患者属于加利西亚两个不同健康地区的PC的四个健康中心(数据来自药房分部的处方医疗认证计划)。研究期间包括2007年1月至2009年3月。分析计算机医疗记录和纸质记录,以确定PPI的处方,以及患者是否因CE(AMI、ACS、中风、TIA、搭桥术、中风和/或外周动脉疾病)而出现任何NH。结果符合入选标准的304例患者(男性65.5%,女性34.5%)入选。58.6%的患者接受了氯吡格雷和PPI治疗。其中58.6%的患者因CE需要住院治疗,而14.3%的患者与PPI无关。这意味着患NH的风险要高2.1倍。奥美拉唑是最常用的PPI(73.65%)。结论所得结果表明PPI和氯吡格雷之间可能存在相互作用,尚不能确定其临床重要性。这并不意味着它可能对患者的健康产生严重影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信